*Look at the list of corrupt companies in this article!
Source: New York Times
October 22, 2010, 8:34 AM
GE Healthcare said Friday that it had agreed to buy Clarient, a molecular diagnostics firm, which it says will help the company better diagnose and characterize cancer, in a deal worth about $580 million.
John Dineen, chief executive of GE Healthcare, said the acquisition “will accelerate our expansion into cancer diagnostics and therapy selection tools,” adding that he hoped to build a diagnostics business worth more than $1 billion.
Clarient hired Goldman Sachs as financial adviser and Latham & Watkins as counsel. GE Healthcare hired JP Morgan as adviser and Sidley Austin as counsel.